Skip To Main Content
Contact us
|
Help
Home
About
ADR
ADR Archives
Resources
Contact
Flash e-reader
Choose a chapter:
Introduction
Kidney
Pancreas
Liver
Intestine
Heart
Lung
Deceased Organ Donation
Allocation Policies
Appendix
Table Selection
Choose an organ:
All Organs
Kidney
Pancreas
Kidney/Pancreas
Heart
Lung
Heart/Lung
Intestine
Liver
Choose a group:
Choose a characteristic:
Requires
Adobe Acrobat Reader
Table 7.6a
Immunosuppression Use for Induction, 2000 to 2009
Recipients with Pancreas After Kidney (PAK) Transplants
Year of Transplant
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Transplants
305
305
375
344
420
343
293
261
213
198
With Immunosuppression Info
299
303
372
336
409
337
283
249
205
192
Induction Drugs
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
ALG
Atgam/NRATG/NRATS
1.7%
0.3%
2.4%
0.6%
1.5%
3.3%
0.0%
1.2%
1.0%
0.0%
OKT3
3.0%
0.7%
1.3%
0.9%
0.2%
0.0%
0.7%
0.4%
1.0%
1.0%
Thymoglobulin
37.1%
50.5%
51.9%
50.9%
57.2%
53.7%
56.2%
61.4%
51.7%
61.5%
Zenapax
32.4%
33.3%
25.3%
9.5%
6.6%
6.8%
2.5%
2.0%
3.9%
3.1%
Simulect
17.1%
13.2%
8.3%
8.0%
5.4%
2.7%
6.7%
4.0%
8.3%
7.8%
Campath
0.0%
0.0%
0.0%
13.4%
19.1%
18.4%
13.4%
12.0%
15.1%
11.5%
No Induction Drugs Recorded
33.4%
25.1%
27.2%
25.9%
20.3%
22.0%
21.9%
20.5%
20.5%
17.2%
Source: OPTN/SRTR Data as of October 1, 2010.
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.
Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.